SCHEMBL7422841

SCHEMBL7422841

O=C(CCCCl)c1ccc2c(c1)OCO2

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.66
KDM4E B2RXH2 1/20 0.66
CTNNB1 P35222 10/20 0.66
WNT3A P56704 9/20 0.66
HPGD P15428 2/20 0.58
MAOB P27338 2/20 0.58
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
MAPK1 P28482 1/20 0.56
PKM P14618 1/20 0.55
TSHR P16473 1/20 0.55
LMNA P02545 1/20 0.55
TP53 P04637 1/20 0.55
MAPT P10636 1/20 0.55
KLF5 Q13887 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7483165 0.91 HPGD (0.68) ALDH1A1CTNNB1WNT3AHPGDPKM
SCHEMBL10733692 0.90 CTNNB1 (0.69) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL4855229 0.86 HPGD (0.66) ALDH1A1CTNNB1WNT3AHPGDPKM
SCHEMBL6486626 0.85 CTNNB1 (0.66) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL15162004 0.84 ALDH1A1 (0.70) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL7385092 0.83 ALDH1A1 (0.64) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL15272906 0.83 ALDH1A1 (0.68) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL10961709 0.82 CTNNB1 (0.71) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL16429605 0.82 ALDH1A1 (0.67) ALDH1A1KDM4ECTNNB1WNT3AHPGD
SCHEMBL6905348 0.82 ALDH1A1 (0.63) ALDH1A1KDM4ECTNNB1WNT3AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177542-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) 2025-06-05 US disclosed
EP-4471035-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2024-12-04 EP disclosed
WO-2023143208-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE 苏州宜联生物医药有限公司 2023-08-03 WO disclosed
WO-2000004015-A1 1-4-DIHYDROPYRIDINES WITH BENZODIOXO CARBONYL GROUP AS CALCIUM BLOCKERS LABORATOIRE L. LAFON (FR) 2000-01-27 WO disclosed
US-4684651-A Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) 1987-08-04 US disclosed
EP-0061149-B1 ALKYLENEDIOXYBENZENE DERIVATIVES AND ACID ADDITION SALTS THEREOF AND A PROCESS FOR THEIR PREPARATION MITSUBISHI KASEI CORPORATION (JP) 1984-11-28 EP disclosed
EP-0061149-A1 Alkylenedioxybenzene derivatives and acid addition salts thereof and a process for their preparation MITSUBISHI KASEI CORPORATION (JP) 1982-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177542-A1 PREPARATION METHOD FOR DRUG LINKER CONJUGATE KIF5B, SI, KIF5C ALDH1A1 438/4885KDM4E 707/4885CTNNB1 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.